| Mathews John, MD | |
|
620 8th Ave, Terre Haute, IN 47804-2744 | |
| (812) 231-8278 | |
| (812) 231-8178 |
| Full Name | Mathews John |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 33 Years |
| Location | 620 8th Ave, Terre Haute, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174571574 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 01054293 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Union Hospital Inc | Terre haute, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wabash Valley Psychiatry Llc | 1254474588 | 2 |
News Archive
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
A full-scale blame game erupted into public view Sunday after nearly three months of secretive negotiations on the supercommittee that failed to resolve an impasse to cut at least $1.2 trillion in deficits over the next decade. Fanning out across the Sunday talk shows just hours before the supercommittee's deadline, Republicans insisted that Democrats wanted to institute a $1 trillion tax hike, while Democrats argued that the GOP wanted to gut popular entitlements and protect the rich.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Cognitive impairment is most likely to affect people with multiple types of brain pathology, irrespective of which particular pathologies they have, a study shows.
A setback in the scientific basis for SNP (single nucleotide polymorphisms) analysis may turn out to be a blessing in disguise for makers of genotyping equipment, reagents and software, according to Kalorama Information.
› Verified 7 days ago
| Entity Name | Wabash Valley Psychiatry Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811223944 PECOS PAC ID: 1254474588 Enrollment ID: O20100208000711 |
News Archive
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
A full-scale blame game erupted into public view Sunday after nearly three months of secretive negotiations on the supercommittee that failed to resolve an impasse to cut at least $1.2 trillion in deficits over the next decade. Fanning out across the Sunday talk shows just hours before the supercommittee's deadline, Republicans insisted that Democrats wanted to institute a $1 trillion tax hike, while Democrats argued that the GOP wanted to gut popular entitlements and protect the rich.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Cognitive impairment is most likely to affect people with multiple types of brain pathology, irrespective of which particular pathologies they have, a study shows.
A setback in the scientific basis for SNP (single nucleotide polymorphisms) analysis may turn out to be a blessing in disguise for makers of genotyping equipment, reagents and software, according to Kalorama Information.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mathews John, MD Po Box 4323, Terre Haute, IN 47804-0323 Ph: (812) 231-8323 | Mathews John, MD 620 8th Ave, Terre Haute, IN 47804-2744 Ph: (812) 231-8278 |
News Archive
Want to know how healthy your heart is? Now there's an app for that. In a proof-of-concept clinical trial, engineers at Caltech, Huntington Medical Research Institute, and USC have demonstrated that the camera on your smartphone can noninvasively provide detailed information about your heart's health.
A full-scale blame game erupted into public view Sunday after nearly three months of secretive negotiations on the supercommittee that failed to resolve an impasse to cut at least $1.2 trillion in deficits over the next decade. Fanning out across the Sunday talk shows just hours before the supercommittee's deadline, Republicans insisted that Democrats wanted to institute a $1 trillion tax hike, while Democrats argued that the GOP wanted to gut popular entitlements and protect the rich.
Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.
Cognitive impairment is most likely to affect people with multiple types of brain pathology, irrespective of which particular pathologies they have, a study shows.
A setback in the scientific basis for SNP (single nucleotide polymorphisms) analysis may turn out to be a blessing in disguise for makers of genotyping equipment, reagents and software, according to Kalorama Information.
› Verified 7 days ago
Dr. Shahzad A Parvaz, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4511 S 7th St, Terre Haute, IN 47802 Phone: 812-917-5109 Fax: 812-917-5071 | |
Ronald Morton Shafer, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3461 Bridlewood Lane, Terre Haute, IN 47802 Phone: 812-243-1590 Fax: 812-234-6614 | |
Lowell Becker, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 500 8th Ave, Terre Haute, IN 47804 Phone: 812-231-8295 Fax: 812-231-8178 | |
Timothy B Hudson, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2901 Ohio Blvd, Suite 202, Terre Haute, IN 47803 Phone: 812-232-2144 Fax: 812-234-4598 | |
William C. Shriner, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 620 8th Ave, Terre Haute, IN 47804 Phone: 812-231-8399 Fax: 812-231-8178 | |
Ruthgayle Stith, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 620 8th Ave, Terre Haute, IN 47804 Phone: 812-231-8267 Fax: 812-231-8178 |